|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
IBC's The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics | ||||||||||||||||
January 10, 2002 | ||||||||||||||||
IBC USA Conferences, Inc., Hilton San Diego Resort, San Diego, CA May 8-10, 2002 Post-translational modifications of recombinant therapeutic proteins present the biotechnology industry with some of its most complex and current challenges in production, manufacture, and analysis of such therapeutics. Recognizing the biological significance of post-translational modifications and its associated economic impact to the industry, IBC has brought together industry and academic leaders to share their experiences at a unique conference. IBC’s The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics is the only conference where you can learn how to exploit post-translational changes for improving your therapeutic protein and understand how to prevent costly delays caused by unwanted modifications. |
||||||||||||||||
Organized by: | IBC USA Conferences, Inc. | |||||||||||||||
Invited Speakers: | Keynote Address The CBER Perspective on Post-Translational and Chemical Modification of Protein Biologics - Keith Webber, Ph.D., Deputy Director, Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, CBER, FDA |
|||||||||||||||
Deadline for Abstracts: | - | |||||||||||||||
Registration: | Five Easy Ways to Register! Phone (508) 616-5550 Fax (508) 616-5522 E-mail reg@ibcusa.com IBC USA Conferences, Inc. One Research Drive, Suite 400A Westborough, MA 01581-5195 |
|||||||||||||||
E-mail: | jprudhomme@ibcusa.com | |||||||||||||||
Posted by: | James G. Prudhomme | |||||||||||||||
Host: | ntserver.ibcusa.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |